Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7875344 | 0.87 | CA1 (0.41) | CA1CA2CA4KMT2AALDH1A1 | |
| SCHEMBL722265 | 0.78 | ALDH1A1 (0.32) | ALDH1A1GAAMAPTTP53HPGD | |
| SCHEMBL25610287 | 0.77 | CA1 (0.30) | CA1CA2CA4 | |
| SCHEMBL8318307 | 0.77 | ALDH1A1 (0.31) | ALDH1A1GAAMAPTTP53HPGD | |
| SCHEMBL8316823 | 0.77 | ALDH1A1 (0.31) | ALDH1A1GAAMAPTTP53HPGD | |
| SCHEMBL8318312 | 0.77 | ALDH1A1 (0.31) | ALDH1A1GAAMAPTTP53HPGD | |
| SCHEMBL7759296 | 0.77 | ALDH1A1 (0.31) | ALDH1A1GAAMAPTTP53HPGD | |
| SCHEMBL8316819 | 0.77 | ALDH1A1 (0.31) | ALDH1A1GAAMAPTTP53HPGD | |
| SCHEMBL11141833 | 0.77 | TLR4 (0.33) | ALDH1A1GAAMAPTTP53HPGD | |
| SCHEMBL4664526 | 0.77 | ALDH1A1 (0.31) | ALDH1A1GAAMAPTTP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| CN-110418780-B | Cyclohexene derivatives as perfuming ingredients | 弗门尼舍有限公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-3596036-B1 | CYCLOHEXENE DERIVATIVES AS PERFUMING INGREDIENTS | FIRMENICH & CIE (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-10934240-B2 | Cyclohexene derivatives as perfuming ingredients | FIRMENICH SA (CH) | 2021-03-02 | — | — | US | disclosed |
| US-20200071253-A1 | CYCLOHEXENE DERIVATIVES AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2020-03-05 | — | — | US | disclosed |
| WO-1993007119-A1 | NOVEL ANTIMALARIAL PEROXIDES AND PROCESSES FOR THEIR PRODUCTION AND USE | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934240-B2 | Cyclohexene derivatives as perfuming ingredients | C5, C1S, C1R | CA1 2719/4885CA2 1656/4885CA4 2505/4885 |
| US-20200071253-A1 | CYCLOHEXENE DERIVATIVES AS PERFUMING INGREDIENTS | C5, C1S, C1R | CA1 2719/4885CA2 1656/4885CA4 2505/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | CA1 1478/4885CA2 276/4885CA4 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.